Dean Capital Investments Management LLC Sells 5,134 Shares of GlaxoSmithKline plc (NYSE:GSK)

Dean Capital Investments Management LLC cut its holdings in GlaxoSmithKline plc (NYSE:GSK) by 22.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,613 shares of the pharmaceutical company’s stock after selling 5,134 shares during the quarter. GlaxoSmithKline comprises 0.4% of Dean Capital Investments Management LLC’s portfolio, making the stock its 25th largest position. Dean Capital Investments Management LLC’s holdings in GlaxoSmithKline were worth $752,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in GSK. Jane Street Group LLC boosted its stake in GlaxoSmithKline by 7,574.0% in the second quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock valued at $72,693,000 after acquiring an additional 1,792,754 shares during the last quarter. Fisher Asset Management LLC boosted its stake in GlaxoSmithKline by 10.2% in the third quarter. Fisher Asset Management LLC now owns 15,267,588 shares of the pharmaceutical company’s stock valued at $651,621,000 after acquiring an additional 1,412,368 shares during the last quarter. Renaissance Technologies LLC boosted its stake in GlaxoSmithKline by 6.9% in the second quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock valued at $610,776,000 after acquiring an additional 989,181 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in GlaxoSmithKline by 362.1% in the second quarter. Point72 Asset Management L.P. now owns 1,105,172 shares of the pharmaceutical company’s stock valued at $44,229,000 after acquiring an additional 866,015 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in GlaxoSmithKline by 502.4% in the second quarter. Invesco Ltd. now owns 644,331 shares of the pharmaceutical company’s stock valued at $25,786,000 after acquiring an additional 537,370 shares during the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Plc Glaxosmithkline acquired 177,777 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average cost of $45.00 per share, for a total transaction of $7,999,965.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

Shares of NYSE GSK traded up $0.30 during midday trading on Tuesday, reaching $44.56. 25,796 shares of the stock were exchanged, compared to its average volume of 2,851,697. The business has a 50-day simple moving average of $43.07 and a two-hundred day simple moving average of $41.17. The company has a market capitalization of $110.79 billion, a price-to-earnings ratio of 14.09, a P/E/G ratio of 2.99 and a beta of 0.70. GlaxoSmithKline plc has a 12 month low of $36.41 and a 12 month high of $46.01. The company has a debt-to-equity ratio of 1.38, a current ratio of 0.82 and a quick ratio of 0.56.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.10. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. The business had revenue of $11.57 billion for the quarter, compared to analyst estimates of $11.34 billion. Equities research analysts expect that GlaxoSmithKline plc will post 3.08 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on GSK shares. New Street Research raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Wednesday, October 16th. Goldman Sachs Group reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 30th. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 23rd. Argus lifted their price target on shares of GlaxoSmithKline from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $43.16.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What are some reasons analysts would give stocks a buy rating?

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.